Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Bevacizumab and Pemetrexed in Advanced NSCLC
NCT00614822Phase 2Completed
- Sponsor
- ChristianaCare
- Start
- Nov 2007
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by ChristianaCare. Primary endpoints: Progression Free Survival at 1 year and Overall Survival at 1 year. Started Nov 2007; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00614822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00614822.